Guselkumab for moderately to severely active ulcerative colitis

被引：0
|
作者：
不详
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2025年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：112 / 112
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [22] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [23] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [24] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [25] Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Ernest-Suarez, Kenneth
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [26] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
    Allegretti, Jessica R.
    Peyrin-Biroulet, Laurent
    Feagan, Brian G.
    Bressler, Brian
    Lichtenstein, Gary R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Shipitofsky, Nicole
    Jiang, Lingjing
    Zhang, Hongyan
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Sands, Bruce E.
    Rubin, David T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
  • [27] Early Symptomatic Improvement With Guselkumab Induction Treatment in Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
    Lichtenstein, Gary R.
    Dignass, Axel
    Rubin, David T.
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Miao, Ye
    Zhang, Hongyan
    Kierkus, Jaroslaw
    Seidler, Ursula
    Maemoto, Atsuo
    Allegretti, Jessica R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S623 - S624
  • [28] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
  • [29] GUSELKUMAB IMPROVES SYMPTOMS OF FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12
    Dignass, Axel
    Panes, Julian
    Rubin, David T.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Pandya, Dwiti
    Han, Chenglong
    Miao, Ye
    Zhang, Hongyan
    Gu, Fang
    Rowbotham, David S.
    Mihaly, Emese
    Bressler, Brian
    Lichtenstein, Gary R.
    Allegretti, Jessica R.
    GASTROENTEROLOGY, 2024, 166 (05) : S848 - S849
  • [30] Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12
    Dignass, A.
    Panes, J.
    Rubin, D. T.
    Huang, K. H. G.
    Germinaro, M.
    Pandya, D.
    Han, C.
    Miao, Y.
    Zhang, H.
    Gu, F.
    Rowbotham, D.
    Mihaly, E.
    Bressler, B.
    Lichtenstein, G. R.
    Allegretti, J. R.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I165 - I166
12345